Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.54 |
| ▸ | MAOB | P27338 | 2/20 | 0.54 |
| ▸ | CES1 | P23141 | 2/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.35 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.35 |
| ▸ | TDP2 | O95551 | 1/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3128 | 0.75 | — | — | |
| SCHEMBL2851479 | 0.75 | — | — | |
| SCHEMBL1451688 | 0.73 | MAOA (0.46) | MAOAMAOBCES1BCHESMN1; SMN2 | |
| SCHEMBL22284 | 0.70 | MAOA (1.00) | MAOAMAOBCES1BCHESMN1; SMN2 | |
| SCHEMBL6903786 | 0.70 | MAOA (1.00) | MAOAMAOBCES1BCHESMN1; SMN2 | |
| SCHEMBL11522370 | 0.70 | MAOA (1.00) | MAOAMAOBCES1BCHESMN1; SMN2 | |
| SCHEMBL6353583 | 0.70 | MAOA (1.00) | MAOAMAOBCES1BCHESMN1; SMN2 | |
| SCHEMBL29448271 | 0.70 | MAOA (1.00) | MAOAMAOBCES1BCHESMN1; SMN2 | |
| Fluoride SCHEMBL8592140 | 0.68 | MAOA (0.95) | MAOAMAOBCES1SMN1; SMN2TDP1 | |
| Hydrochloric Acid SCHEMBL11215152 | 0.68 | MAOA (0.95) | MAOAMAOBCES1SMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3445762-B1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-13 | — | — | EP | claimed |
| CN-106795174-B | Antiviral active diazacyclospirodiketopiperazine alkaloid derivative and preparation method thereof | 扬州蓝色生物医药科技有限公司 | 2020-04-28 | — | — | CN | claimed |
| EP-1660464-B1 | CASPASE INHIBITORS CONTAINING ISOXAZOLINE RING | LG LIFE SCIENCES LTD (KR) | 2015-02-25 | — | — | EP | claimed |
| US-20110130426-A1 | Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases | ASTRAZENECA AB (SE) | 2011-06-02 | — | — | US | claimed |
| US-7569561-B2 | 2,4-diaminopyrimidines useful for treating cell proliferation diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-04 | — | — | US | claimed |
| US-20090170898-A1 | Sulphonamide Derivatives as Modulators of the Glucocorticoid Receptor | BENGTSSON MALENA | 2009-07-02 | — | — | US | claimed |
| US-7553831-B2 | Beta-secretase inhibitors; inhibiting cleavage of amyloid precursor protein (APP); hydroxy-functional disubstituted amines such as 6-(([[(2S,3S)-4-(3,5-difluorophenyl)-3-((3-[(dipropylamino)carbonyl]benzoyl)amino)-2-hydroxybutyl](ethyl)amino]carbonyl)amino)hexanoic acid | ELAN PHARMACEUTICALS, INC. (US) | 2009-06-30 | — | — | US | claimed |
| US-20090093485-A1 | Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases | ASTRAZENECA AB (SE) | 2009-04-09 | — | — | US | claimed |
| US-20090074746-A1 | Compounds to treat alzheimer's disease | ALZHEIMER'S COLLABORATION | 2009-03-19 | — | — | US | claimed |
| US-7388118-B2 | Amine 1,2- and 1,3-diol compounds | PHAMACIA & UPJOHN COMPANY LLC (US) | 2008-06-17 | — | — | US | claimed |
| WO-2002002506-A2 | COMPOUNDS TO TREAT ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-01-10 | — | — | WO | claimed |
| EP-0739203-A4 | METHOD FOR TREATING DISEASES MEDIATED BY CELLULAR PROLIFERATION IN RESPONSE TO PDGF, EGF, FGF AND VEGF | CELL THERAPEUTICS INC (US) | 2000-12-20 | — | — | EP | claimed |
| US-5985926-A | VIRICIDES OF AMINE COMPOUNDS AND HYDROCARBONS | CELL THERAPEUTICS, INC. (US) | 1999-11-16 | — | — | US | claimed |
| US-5856331-A | LYSOPHOSPHATIDIC ACYLTRANSFERASE INHIBITOR | CELL THERAPEUTICS, INC. (US) | 1999-01-05 | — | — | US | claimed |
| EP-0739203-A1 | METHOD FOR TREATING DISEASES MEDIATED BY CELLULAR PROLIFERATION IN RESPONSE TO PDGF, EGF, FGF AND VEGF | CELL THERAPEUTICS, INC. (US) | 1996-10-30 | — | — | EP | claimed |
| EP-0728003-A1 | METHOD FOR PREVENTING TISSUE INJURY FROM HYPOXIA | CELL THERAPEUTICS, INC. (US) | 1996-08-28 | — | — | EP | claimed |
| EP-0676958-A1 | METHOD FOR INHIBITING INTRACELLULAR VIRAL REPLICATION | CELL THERAPEUTICS, INC. (US) | 1995-10-18 | — | — | EP | claimed |
| WO-1995019171-A1 | METHOD FOR TREATING DISEASES MEDIATED BY CELLULAR PROLIFERATION IN RESPONSE TO PDGF, EGF, FGF AND VEGF | CELL THERAPEUTICS, INC. (US) | 1995-07-20 | — | — | WO | claimed |
| WO-1995013075-A1 | METHOD FOR PREVENTING TISSUE INJURY FROM HYPOXIA | CELL THERAPEUTICS, INC. (US) | 1995-05-18 | — | — | WO | claimed |
| WO-1995012396-A1 | METHOD FOR INHIBITING INTRACELLULAR VIRAL REPLICATION | CELL THERAPEUTICS, INC. (US) | 1995-05-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170898-A1 | Sulphonamide Derivatives as Modulators of the Glucocorticoid Receptor | NR3C1, NR3C2, NR5A1 | MAOA 3962/4885MAOB 3494/4885CES1 1436/4885 |
| US-20090093485-A1 | Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases | NR3C1, NR3C2, NR5A1 | MAOA 4318/4885MAOB 4093/4885CES1 1130/4885 |
| US-20090074746-A1 | Compounds to treat alzheimer's disease | PSEN2, PSEN1, CHAT | MAOA 12/4885MAOB 14/4885CES1 1671/4885 |
| US-20110130426-A1 | Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases | NR3C1, NR3C2, NR5A1 | MAOA 4380/4885MAOB 4200/4885CES1 1291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.